Sandoz and Vietnam National Cancer Hospital sign new MoU to enhance professional education and capabilities in cancer
Xem Tiếng Việt 
- Partnership reinforces commitment of Sandoz to reducing cancer burden in Vietnam
- Second such partnership with a Vietnamese hospital to improve local and international knowledge-sharing since becoming a standalone company
- Sandoz Vietnam currently employs 140 associates.
Sandoz, the global leader in generic and biosimilar medicines, and the Vietnam National Cancer Hospital today signed a partnership that sees the global pharmaceutical company working to improve the standards of care offered to oncology patients in Hanoi and around the nation.
Sandoz, which became a wholly-independent enterprise globally last year, and received its Vietnam license earlier this year, entered the market under the stewardship of General Director Charaf Eddine Kadri, with a commitment to pioneering access to patients through affordable generic and biosimilar treatments in areas including oncology, anti-infectives and a wide array of other therapeutic areas.
The hospital, located in the capital’s central Hoan Kiem District, celebrated its 100th anniversary in November last year and is Vietnam’s largest oncology hospital, with over 450,000 medical examinations for patients per year.
“This partnership is about improving the connections and cooperation between domestic and foreign oncology organizations and experts, and builds upon more than a decade of collaboration between Sandoz and Vietnam’s National Cancer Hospital,” said Charaf Eddine Kadri.
The country currently sees over 190,000 new cancer diagnoses each year, with the disease claiming the lives of more than 120,000 people in Vietnam each year and is second only to cardio-vascular disease as the leading cause of non-communicable disease death in the nation[1].
Sandoz is a longstanding leader in oncology, with Kadri noting that: “Over five million patients in Vietnam receive Sandoz treatments annually, including various cancer conditions which are covered by our treatments in Vietnam’s public hospital system.”
“The partnership will ultimately see Sandoz sponsor and support information seminars that help doctors at the country’s leading specialized oncology hospital, and, by extension, around Vietnam’s northern regions to discuss and develop prevention and treatment plans for patients,” Kadri continued.
“Vietnam National Cancer Hospital is the country’s leading specialized hospital in the field of oncology, with highly qualified medical experts and a modern equipment system. Our hospital always accompanied with the leading pharmaceutical companies in education, technique transfer, and scientific research in order to deliver the highest treatments for Vietnamese patients”, said Professor Le Van Quang, Director of Vietnam National Cancer Hospital.
This is the second such partnership that the company has entered into, following the signing of a similar partnership with Ho Chi Minh City Oncology Hospital in March of this year, which has already seen the company support its Annual Cancer Congress.
[1] https://med.stanford.edu/content/dam/sm/care/VN-Data-Brief.pdf
